Polaryx Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.polaryx.com
Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3
Phase 3
Not yet recruiting
- Conditions
- Juvenile Neuronal Ceroid Lipofuscinosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Polaryx Therapeutics, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04637282
© Copyright 2025. All Rights Reserved by MedPath